Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025

Core Viewpoint - Iovance Biotherapeutics, Inc. is set to report its second quarter and first half 2025 financial results and corporate updates on August 7, 2025, highlighting its focus on innovative TIL therapies for cancer patients [1][2]. Company Overview - Iovance Biotherapeutics aims to be a global leader in developing tumor infiltrating lymphocyte (TIL) therapies, utilizing the human immune system to target diverse cancer cells [3]. - The company's TIL platform has shown promising clinical data across various solid tumors, with Amtagvi being the first FDA-approved T cell therapy for a solid tumor indication [3]. Upcoming Events - Management will host a conference call and live audio webcast on August 7, 2025, at 4:30 p.m. ET to discuss the financial results and provide a corporate update [2]. - The live and archived webcast will be accessible through the company's website, with the archived version available for one year [2].